• CHK1 Inhibition and Hormone Receptor Status in Breast Cancer

  2026-04-30

  This study delineates how the therapeutic efficacy of CHK1 inhibition in breast cancer is fundamentally modulated by estrogen and progesterone receptor status. By integrating transcriptome analyses and functional assays, the research details context-specific mechanisms that inform the strategic application of CHK1 inhibitors in targeted oncology.

• Pharmacokinetics of Corydalis saxicola Alkaloids in MASH Mod

  2026-04-30

  This study systematically investigates the pharmacokinetic variability and tissue distribution of key alkaloids from Corydalis saxicola Bunting in a murine model of metabolic dysfunction-associated steatohepatitis (MASH). The findings highlight how disease pathology and dosing regimen modulate systemic exposure, hepatic accumulation, and transporter/enzyme expression, providing an evidence base for rationalizing dosing strategies in MASH therapy.

• IWR-1-endo: Mechanistic Dissection and Advanced Protocols fo

  2026-04-29

  Explore the in-depth mechanism and advanced research applications of IWR-1-endo, a potent Wnt signaling inhibitor. This article uniquely connects molecular insight to practical assay decisions, advancing beyond standard reviews.

• VEGFC–VEGFR-3 Axis Disruption Mitigates NASH-Driven Hepatic

  2026-04-29

  This study uncovers the central role of the hepatocyte-derived VEGFC–VEGFR-3 axis in driving hepatic fibrosis in NASH, demonstrating that its inhibition—via genetic or pharmacological strategies—attenuates inflammation and fibrotic progression. These findings position VEGFR-3 inhibition as a mechanistically validated approach for dissecting anti-fibrotic pathways in metabolic liver disease.

• ALDOB K87 Lactylation Drives Mitochondrial Fission in PH

  2026-04-28

  This study identifies ALDOB K87 lactylation as a pivotal driver of mitochondrial fission and metabolic reprogramming in pulmonary hypertension (PH). Through proteomic profiling and mechanistic validation, the authors link lactate metabolism to smooth muscle cell proliferation and vascular remodeling, providing new targets for PH research.

• Cyclosporin A: Optimizing Immunosuppression and Mitochondria

  2026-04-28

  Cyclosporin A is more than an immunosuppressive cyclic undecapeptide—it is a precision tool for dissecting T-cell activation, mitochondrial permeability, and signaling. This article delivers actionable workflows, troubleshooting, and key innovations for advanced research, linking bench protocols with translational impact.

• Amyloid β-Peptide (1-42): Optimizing Neurotoxicity and Micro

  2026-04-27

  Amyloid β-Peptide (1-42) (Aβ42) is pivotal for modeling Alzheimer's disease mechanisms, from neuronal toxicity to microglial activation. This article delivers actionable, experiment-ready workflows and troubleshooting strategies, translating recent reference breakthroughs into reproducible, high-impact assays.

• AZD0156: Precision ATM Kinase Inhibitor for Cancer Research

  2026-04-27

  AZD0156 offers unmatched potency and selectivity as an ATM kinase inhibitor, empowering researchers to dissect DNA repair and metabolic adaptation in advanced cancer models. Explore evidence-backed workflows, synergistic applications, and troubleshooting strategies that maximize the impact of this tool in DNA damage response and therapeutic discovery.

• Brefeldin A (BFA): Reliable ER Stress and Apoptosis Inductio

  2026-04-26

  This article presents scenario-driven, evidence-based guidance for deploying Brefeldin A (SKU B1400) as an ER stress inducer and apoptosis modulator in cancer and cell biology assays. Drawing from recent literature and product specifications, it addresses real-world optimization challenges and highlights the reproducibility and workflow advantages of Brefeldin A from APExBIO.

• Nutlin-3a in Precision Oncology: Unraveling MDM2 Inhibition

  2026-04-25

  Explore how Nutlin-3a, a leading MDM2 inhibitor, enables cutting-edge research into p53 pathway activation, apoptosis, and advanced cancer biology. This article delivers unique assay insights and strategic context distinct from prior Nutlin-3a coverage.

• ATRX Deficiency Sensitizes Glioma Cells to RTK and PDGFR Inh

  2026-04-24

  This study demonstrates that high-grade glioma cells lacking ATRX are significantly more sensitive to multi-targeted receptor tyrosine kinase (RTK) and platelet-derived growth factor receptor (PDGFR) inhibitors. These findings suggest ATRX status should be considered in clinical trial stratification and design for targeted therapies in glioma.

• Gentamycin Sulfate (SKU A2514): Reliable Solutions in Cell A

  2026-04-24

  This article provides biomedical researchers and laboratory professionals with scenario-driven guidance on leveraging Gentamycin Sulfate (SKU A2514) for robust cell viability, proliferation, and resistance assays. Drawing from validated protocols and recent resistance research, it details how Gentamycin Sulfate ensures reproducibility and workflow safety, with practical tips for protocol optimization and product selection.

• Thioguanine (6-thioguanine): Applied Protocols in Antitumor

  2026-04-23

  Thioguanine (6-thioguanine) enables high-selectivity antiviral and antitumor workflows by targeting both nucleotide metabolism and epigenetic regulation. This article delivers actionable protocols, troubleshooting insights, and a direct translation of the latest evidence in EV71 virus inhibition and cancer cell proliferation assays.

• Systematic Evaluation of AKT Inhibitors Reveals Class-Specif

  2026-04-23

  This study systematically dissects the molecular and pharmacologic profiles of clinical AKT inhibitors, revealing distinct differences between ATP-competitive and allosteric compounds in terms of specificity, resistance, and cellular effects. The findings deepen mechanistic understanding of AKT inhibition in oncology research and inform the rational design of targeted therapy combinations.

• SP600125: Precision JNK Inhibitor for Apoptosis & Inflammati

  2026-04-22

  SP600125, a highly selective JNK inhibitor from APExBIO, enables targeted dissection of JNK-driven pathways in apoptosis and inflammation. Its robust selectivity and proven workflow adaptability make it indispensable for cytokine modulation, disease modeling, and translational research.

16227 records 1/1082 page Next 12345 下5页 Last page